Press Release Archive

03.28.2014

Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium® 24HR

03.27.2014

In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control 1

03.27.2014

Bococizumab (RN316) Significantly Reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study

03.26.2014

Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN® In Very Young Children Born Small For Gestational Age

03.25.2014

Pfizer Invites Public To View And Listen To Webcast Of May 5 Conference Call With Analysts

03.25.2014

Pfizer Reports Positive Phase 3 Study Outcome Of XALKORI® (crizotinib) Compared To Chemotherapy In Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

03.22.2014

Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL® in Adults with Moderate-to-Severe Chronic Plaque Psoriasis

03.20.2014

Pfizer’s Investigational Vaccine Candidate Bivalent rLP2086 Receives U.S. Food and Drug Administration Breakthrough Therapy Designation for Potential Prevention of Meningococcal B Disease

03.18.2014

Pfizer Launches 2013 Integrated Annual Review

03.14.2014

U.S. FDA Approves Eliquis® (apixaban) To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery

03.12.2014

Pfizer Will Appeal Court Decision Regarding Celebrex Reissue Patent

03.12.2014

Pfizer Announces Webcast Of April 6 Conference Call With Securities Analysts To Review Palbociclib Phase 2 Final Results Following Presentation At AACR Annual Meeting 2014

03.12.2014

Pfizer Presents Detailed Results From Landmark Community-Acquired Pneumonia Immunization Trial In Adults (CAPiTA) Evaluating Efficacy Of Prevenar 13*

03.06.2014

Pfizer Initiates Nationwide Voluntary Recall Of Two Lots Of Pfizer's Effexor XR® 150 mg Extended-Release Capsules And One Lot Of Greenstone's Venlafaxine HCI 150 mg Extended-Release Capsules Due To The Possible Presence Of Tikosyn® Capsule

02.26.2014

Saniona Announces Collaboration With Pfizer To Research And Develop Small Molecule Treatments For Neurological Disorders.

02.24.2014

Pfizer Announces FDA Approval To Include Radiographic Data On Reduction Of Progression Of Structural Joint Damage For Adults With Moderately To Severely Active Rheumatoid Arthritis In Labeling For XELJANZ® (tofacitinib citrate)

02.24.2014

Pfizer Announces Positive Top-Line Results Of Landmark Community-Acquired Pneumonia Immunization Trial In Adults (CAPiTA) Evaluating Efficacy Of Prevenar 13*

02.21.2014

In a Subanalysis, Eliquis® (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events Versus Warfarin Consistently Across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation[i]

02.15.2014

Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies

02.11.2014

Pfizer Statement on Today’s Joint Meeting of FDA Advisory Committees

02.11.2014

New Funding For Fundamental Biomedical Research To Be Made Available

02.05.2014

Ichor Enters Into An Agreement With Pfizer To Develop Electroporation Devices For Use In Therapeutic Cancer Vaccine Regimens

02.05.2014

Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies

02.03.2014

Pfizer Announces Positive Top-Line Results From PALOMA-1 Evaluating Palbociclib Plus Letrozole in Women with Advanced Breast Cancer

01.28.2014

U.Va. Spinoff Neoantigenics Announces Collaboration with Pfizer, Investment from CIT to Develop Antibody-based Therapeutics For Cancer

01.28.2014

Pfizer Reports Fourth-Quarter and Full-Year 2013 Results; Provides 2014 Financial Guidance

01.27.2014

Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer

01.23.2014

Pfizer Reports Top-Line Results From ALO-02 Phase 3 Study

01.22.2014

New Survey Reveals What Match.Com Members Think About Smoking Cigarettes And Dating

01.21.2014

CHANTIX®/CHAMPIX® (varenicline) Demonstrates Smoking- Cessation Efficacy In Smokers Unwilling or Unable To Quit Abruptly

01.09.2014

Akili Interactive Labs Announces Partnership with Pfizer to Test Video Game in People at Risk of Alzheimer’s Disease

01.06.2014

MD Anderson teams up with Pfizer to advance cancer immunotherapy

12.19.2013

FDA Accepts For Review ELIQUIS® (apixaban) Supplemental New Drug Application For The Treatment Of Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE), And For The Reduction In The Risk Of Recurrent DVT And PE

12.18.2013

Mylan Announces Acquisition of Rights to Novel LAMA Respiratory Compound from Pfizer

12.17.2013

Pfizer Settles Viagra® Patent Litigation With Teva

12.17.2013

Pfizer Names Albert Bourla Group President; Vaccines, Oncology And Consumer Healthcare Business

12.16.2013

Pfizer Declares First-Quarter 2014 Dividend

12.04.2013

Pfizer Expands Clinical Trial Data Access Policy And Launches Data Access Portal

12.02.2013

Pfizer Acquires Polocard, Poland’s Leading Over-The-Counter Heart Attack Prevention Brand

11.25.2013

Just in Time for Peak Travel Season, Introducing New Robitussin® DM Max Liquid-Filled Capsules

11.21.2013

Pfizer’s XALKORI® Granted Regular FDA Approval

11.21.2013

Pfizer And GSK To Initiate Study Of Novel Combination Therapy In Patients With Melanoma

11.18.2013

Pfizer Announces FDA Approval Of Supplemental Application To Expand XELJANZ® (tofacitinib citrate) Labeling To Include Additional Patient-Reported Outcomes Data For Adults With Moderately To Severely Active Rheumatoid Arthritis

11.14.2013

Pfizer Subsidiary, Wyeth LLC, To Redeem 5.500% Notes Due February 1, 2014

11.08.2013

Pfizer Announces Top-Line Results Of Phase 3B/4 Study Of RAPAMUNE® (sirolimus) In Renal Transplant Recipients

11.05.2013

Former U.S. President Jimmy Carter And Pfizer Celebrate 15-Year Effort To Help End Blinding Trachoma As A Public Health Concern

11.04.2013

Pfizer Receives FDA Approval For A Prior Approval Supplement For EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII

11.04.2013

JDRF Teams Up with Pfizer’s Centers for Therapeutic Innovation to Support Novel Translational Research in Type 1 Diabetes